^
Association details:
| Biomarker: | SQSTM1-NTRK1 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)
Excerpt:
Of note, the patient with SQSTM1-NTRK1-rearranged NSCLC had 15–20 brain metastases identified at baseline not previously irradiated; a complete intracranial response was achieved with entrectinib therapy that is ongoing at 15 months as of the data cutoff date.
DOI:
10.1158/2159-8290.CD-16-1237
